-
2
-
-
44749087847
-
-
Global Initiative for Asthma. GINA workshop report, global strategy for asthma management and prevention, 2005. 〈http://www.ginasthma.com〉.
-
Global Initiative for Asthma. GINA workshop report, global strategy for asthma management and prevention, 2005. 〈http://www.ginasthma.com〉.
-
-
-
-
3
-
-
0028264310
-
-
Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219-24.
-
Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994;344:219-24.
-
-
-
-
4
-
-
0029880013
-
Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids
-
Woolcock A., Lundback B., Ringdal N., and Jacques L.A. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 153 (1996) 1481-1488
-
(1996)
Am J Respir Crit Care Med
, vol.153
, pp. 1481-1488
-
-
Woolcock, A.1
Lundback, B.2
Ringdal, N.3
Jacques, L.A.4
-
5
-
-
0032906413
-
The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group
-
Condemi J.J., Goldstein S., Kalberg C., Yancey S., Emmett A., and Rickard K. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Salmeterol Study Group. Ann Allergy Asthma Immunol 82 (1999) 383-389
-
(1999)
Ann Allergy Asthma Immunol
, vol.82
, pp. 383-389
-
-
Condemi, J.J.1
Goldstein, S.2
Kalberg, C.3
Yancey, S.4
Emmett, A.5
Rickard, K.6
-
6
-
-
0033403842
-
Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma
-
Aubier M., Pieters W.R., Schlosser N.J., and Steinmetz K.O. Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma. Respir Med 93 (1999) 876-884
-
(1999)
Respir Med
, vol.93
, pp. 876-884
-
-
Aubier, M.1
Pieters, W.R.2
Schlosser, N.J.3
Steinmetz, K.O.4
-
7
-
-
0034099011
-
Combined salmeterol 50 μg and fluticasone propionate 250 μg in the diskus device for the treatment of asthma
-
Shapiro G., Lumry W., Wolfe J., et al. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med 161 (2000) 527-534
-
(2000)
Am J Respir Crit Care Med
, vol.161
, pp. 527-534
-
-
Shapiro, G.1
Lumry, W.2
Wolfe, J.3
-
8
-
-
0033910893
-
Salmeterol/fluticasone propionate combination therapy 50/250 μg twice daily is more effective than budesonide 800 μg twice daily in treating moderate to severe asthma
-
Jenkins C., Woolcock A.J., Saarelainen P., Lundback B., and James M.H. Salmeterol/fluticasone propionate combination therapy 50/250 μg twice daily is more effective than budesonide 800 μg twice daily in treating moderate to severe asthma. Respir Med 94 (2000) 715-723
-
(2000)
Respir Med
, vol.94
, pp. 715-723
-
-
Jenkins, C.1
Woolcock, A.J.2
Saarelainen, P.3
Lundback, B.4
James, M.H.5
-
9
-
-
0037406502
-
Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma
-
Ind P.W., Dal Negro R., Colman N.C., Fletcher C.P., Browning D., and James M.H. Addition of salmeterol to fluticasone propionate treatment in moderate-to-severe asthma. Respir Med 97 (2003) 555-562
-
(2003)
Respir Med
, vol.97
, pp. 555-562
-
-
Ind, P.W.1
Dal Negro, R.2
Colman, N.C.3
Fletcher, C.P.4
Browning, D.5
James, M.H.6
-
10
-
-
0942298705
-
Salmeterol/fluticasone propionate (50/250 μg) combination is superior to double dose fluticasone (500 μg) for the treatment of symptomatic moderate asthma
-
Bergmann K.C., Lindemann L., Braun R., and Steinkamp G. Salmeterol/fluticasone propionate (50/250 μg) combination is superior to double dose fluticasone (500 μg) for the treatment of symptomatic moderate asthma. Swiss Med Wkly 134 (2004) 50-58
-
(2004)
Swiss Med Wkly
, vol.134
, pp. 50-58
-
-
Bergmann, K.C.1
Lindemann, L.2
Braun, R.3
Steinkamp, G.4
-
11
-
-
0031881261
-
The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies
-
Davies B., Brooks G., and Devoy M. The efficacy and safety of salmeterol compared to theophylline: meta-analysis of nine controlled studies. Respir Med 92 (1998) 256-263
-
(1998)
Respir Med
, vol.92
, pp. 256-263
-
-
Davies, B.1
Brooks, G.2
Devoy, M.3
-
12
-
-
0034538067
-
Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast
-
Nelson H.S., Busse W.W., Kerwin E., et al. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 106 (2000) 1088-1095
-
(2000)
J Allergy Clin Immunol
, vol.106
, pp. 1088-1095
-
-
Nelson, H.S.1
Busse, W.W.2
Kerwin, E.3
-
13
-
-
0037372118
-
The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma
-
Ringdal N., Eliraz A., Pruzinec R., et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med 97 (2003) 234-241
-
(2003)
Respir Med
, vol.97
, pp. 234-241
-
-
Ringdal, N.1
Eliraz, A.2
Pruzinec, R.3
-
14
-
-
0028040895
-
The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease
-
Fjellbirkeland L., Gulsvik A., and Palmer J.B.D. The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease. Respir Med 88 (1994) 599-607
-
(1994)
Respir Med
, vol.88
, pp. 599-607
-
-
Fjellbirkeland, L.1
Gulsvik, A.2
Palmer, J.B.D.3
-
15
-
-
1942520223
-
Efficacy and safety of methylxanthines in the treatment of asthma
-
Sohei M., Makoto F., and Naoto F. Efficacy and safety of methylxanthines in the treatment of asthma. Allergol Int 53 (2004) 13-22
-
(2004)
Allergol Int
, vol.53
, pp. 13-22
-
-
Sohei, M.1
Makoto, F.2
Naoto, F.3
-
16
-
-
0027392992
-
Theophylline. Current thoughts on the risks and benefits of its use in asthma
-
Nasser S.S., and Rees P.J. Theophylline. Current thoughts on the risks and benefits of its use in asthma. Drug Saf 8 (1993) 12-18
-
(1993)
Drug Saf
, vol.8
, pp. 12-18
-
-
Nasser, S.S.1
Rees, P.J.2
-
17
-
-
0025217643
-
Theophylline in the management of airflow obstruction. 2. Difficult drugs to use, few clinical indications
-
Johnston I.D. Theophylline in the management of airflow obstruction. 2. Difficult drugs to use, few clinical indications. BMJ 300 (1990) 929-931
-
(1990)
BMJ
, vol.300
, pp. 929-931
-
-
Johnston, I.D.1
-
19
-
-
33846051559
-
A prospective survey on safety of sustained-release theophylline in treatment of asthma and COPD
-
Makino S., Adachi M., Ohta K., et al. A prospective survey on safety of sustained-release theophylline in treatment of asthma and COPD. Allergol Int 55 (2006) 395-402
-
(2006)
Allergol Int
, vol.55
, pp. 395-402
-
-
Makino, S.1
Adachi, M.2
Ohta, K.3
-
20
-
-
35448975251
-
Comparison of the efficacy of salmeterol/fluticasone propionate combination in Japanese and Caucasian asthmatics
-
Kawai M., Kempsfordb R., Pulleritsc T., et al. Comparison of the efficacy of salmeterol/fluticasone propionate combination in Japanese and Caucasian asthmatics. Respir Med 101 (2007) 2488-2494
-
(2007)
Respir Med
, vol.101
, pp. 2488-2494
-
-
Kawai, M.1
Kempsfordb, R.2
Pulleritsc, T.3
-
21
-
-
44749087794
-
-
® in Japanese and Caucasian asthma patients [Abstract]. Presented at the 4th world asthma meeting, Bangkok, Thailand, 2004.
-
® in Japanese and Caucasian asthma patients [Abstract]. Presented at the 4th world asthma meeting, Bangkok, Thailand, 2004.
-
-
-
-
22
-
-
0029763030
-
Bioavailability of a new sustained-release anhydrous theophylline product
-
Tatsis G., Tsoukalas G., Haviaras A., et al. Bioavailability of a new sustained-release anhydrous theophylline product. J Int Med Res 24 (1996) 331-339
-
(1996)
J Int Med Res
, vol.24
, pp. 331-339
-
-
Tatsis, G.1
Tsoukalas, G.2
Haviaras, A.3
-
24
-
-
0041843809
-
Patient perceptions of an inhaled asthma medication administered as an inhalation powder via the Diskus or as an inhalation aerosol via a metered-dose inhaler
-
Sheth K., Bernstein J.A., Lincourt W.R., et al. Patient perceptions of an inhaled asthma medication administered as an inhalation powder via the Diskus or as an inhalation aerosol via a metered-dose inhaler. Ann Allergy Asthma Immunol 91 (2003) 55-60
-
(2003)
Ann Allergy Asthma Immunol
, vol.91
, pp. 55-60
-
-
Sheth, K.1
Bernstein, J.A.2
Lincourt, W.R.3
-
25
-
-
23844483910
-
Inhaled salmetrol/fluticasone propionate: a review of its use in asthma
-
Reynold N.A., Lyseng-Williamson K.A., and Wiseman L.R. Inhaled salmetrol/fluticasone propionate: a review of its use in asthma. Drugs 65 (2005) 1715-1734
-
(2005)
Drugs
, vol.65
, pp. 1715-1734
-
-
Reynold, N.A.1
Lyseng-Williamson, K.A.2
Wiseman, L.R.3
-
26
-
-
0141749461
-
Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma
-
Lyseng-Williamson K.A., and Plosker G.L. Inhaled salmeterol/fluticasone propionate combination: a pharmacoeconomic review of its use in the management of asthma. Pharmacoeconomics 21 (2003) 951-989
-
(2003)
Pharmacoeconomics
, vol.21
, pp. 951-989
-
-
Lyseng-Williamson, K.A.1
Plosker, G.L.2
|